JP7210612B2 - 抗aベータ抗体及びその使用 - Google Patents
抗aベータ抗体及びその使用 Download PDFInfo
- Publication number
- JP7210612B2 JP7210612B2 JP2020566267A JP2020566267A JP7210612B2 JP 7210612 B2 JP7210612 B2 JP 7210612B2 JP 2020566267 A JP2020566267 A JP 2020566267A JP 2020566267 A JP2020566267 A JP 2020566267A JP 7210612 B2 JP7210612 B2 JP 7210612B2
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- sequence
- cdr2
- cdr1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862678080P | 2018-05-30 | 2018-05-30 | |
| US62/678,080 | 2018-05-30 | ||
| PCT/US2019/034259 WO2019231957A1 (en) | 2018-05-30 | 2019-05-29 | Anti-abeta antibodies and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021525512A JP2021525512A (ja) | 2021-09-27 |
| JP2021525512A5 JP2021525512A5 (cg-RX-API-DMAC7.html) | 2022-05-20 |
| JP7210612B2 true JP7210612B2 (ja) | 2023-01-23 |
Family
ID=68694402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020566267A Active JP7210612B2 (ja) | 2018-05-30 | 2019-05-29 | 抗aベータ抗体及びその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11084873B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3801618A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7210612B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102523019B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN112601550B (cg-RX-API-DMAC7.html) |
| CA (1) | CA3100896C (cg-RX-API-DMAC7.html) |
| TW (1) | TWI721440B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019231957A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| KR20210124308A (ko) | 2019-01-30 | 2021-10-14 | 트루바인딩 아이엔씨. | 항-gal3 항체 및 이의 용도 |
| MX2022014786A (es) | 2020-05-26 | 2023-01-16 | Truebinding Inc | Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3. |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ568012A (en) * | 2005-12-12 | 2012-07-27 | Ac Immune Sa | A beta 1-42 specific monoclonal antibodies with therapeutic properties |
| CN101325972B (zh) * | 2005-12-12 | 2020-06-16 | Ac免疫有限公司 | 具有治疗性质的Aβ1-42特异性单克隆抗体 |
| US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
| EP2527369A3 (en) * | 2007-09-13 | 2012-12-19 | University Of Zurich Prorektorat Forschung | Monoclonal amyloid beta (abeta)-specific antibody and uses thereof |
| CN104109208A (zh) * | 2007-11-14 | 2014-10-22 | 中外制药株式会社 | 使用抗gpr49抗体的癌症的诊断和治疗 |
| AU2008322523B2 (en) * | 2007-11-16 | 2013-10-10 | The Rockefeller University | Antibodies specific for the protofibril form of beta-amyloid protein |
| WO2011016238A1 (en) * | 2009-08-06 | 2011-02-10 | Immunas Pharma, Inc. | Antibodies that specifically bind to a beta oligomers and use thereof |
| EP2928494A4 (en) | 2012-12-07 | 2016-11-02 | Biogen Internat Neuroscience Gmbh | METHOD FOR REDUCING AMYLOIDER PLAQUE OF BRAIN WITH ANTI-ASS ANTIBODIES |
| US9879076B2 (en) * | 2013-03-15 | 2018-01-30 | Ramot At Tel Aviv University Ltd. | Methods and compositions with immune therapy for treatment of dementia |
| MX378944B (es) * | 2014-04-18 | 2025-03-10 | Univ New York State Res Found | Anticuerpos de antígeno anti-tf humanizado. |
| CA3004482A1 (en) * | 2015-11-09 | 2017-05-18 | Neil R. Cashman | N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto |
| PL3430397T3 (pl) * | 2016-03-14 | 2022-04-04 | Biogen International Neuroscience Gmbh | Oznaczenie fagocytozy zależnej od przeciwciał do wiarygodnych pomiarów wychwytu zagregowanych białek |
-
2019
- 2019-05-29 KR KR1020207034600A patent/KR102523019B1/ko active Active
- 2019-05-29 EP EP19811193.2A patent/EP3801618A4/en active Pending
- 2019-05-29 WO PCT/US2019/034259 patent/WO2019231957A1/en not_active Ceased
- 2019-05-29 CN CN201980036565.6A patent/CN112601550B/zh active Active
- 2019-05-29 JP JP2020566267A patent/JP7210612B2/ja active Active
- 2019-05-29 CA CA3100896A patent/CA3100896C/en active Active
- 2019-05-30 TW TW108118733A patent/TWI721440B/zh active
- 2019-05-30 US US16/426,585 patent/US11084873B2/en active Active
Non-Patent Citations (2)
| Title |
|---|
| J. Neuroimmunol.,1998年,Vol. 88,pp.85-90 |
| PLOS ONE,2014年,Vol. 9, Issue 3, e90857 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019277171A1 (en) | 2020-12-03 |
| JP2021525512A (ja) | 2021-09-27 |
| CN112601550B (zh) | 2023-12-08 |
| EP3801618A4 (en) | 2022-07-27 |
| TWI721440B (zh) | 2021-03-11 |
| US20190367593A1 (en) | 2019-12-05 |
| WO2019231957A1 (en) | 2019-12-05 |
| TW202033549A (zh) | 2020-09-16 |
| US11084873B2 (en) | 2021-08-10 |
| KR20210041535A (ko) | 2021-04-15 |
| CA3100896C (en) | 2023-08-29 |
| CA3100896A1 (en) | 2019-12-05 |
| EP3801618A1 (en) | 2021-04-14 |
| CN112601550A (zh) | 2021-04-02 |
| KR102523019B1 (ko) | 2023-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7532571B2 (ja) | 抗N3pGluアミロイドベータペプチド抗体およびその使用 | |
| JP7610279B2 (ja) | アルファ-シヌクレインに対する抗体およびその用途 | |
| JP6261621B2 (ja) | アルファ−シヌクレイン抗体及びその使用 | |
| CA2812865C (en) | Phosphospecific antibodies recognising tau | |
| JP6449441B2 (ja) | FcRn特異的ヒト抗体及びこれを含む自己免疫疾患治療用組成物 | |
| US20100104577A1 (en) | Methods and materials related to anti-a (beta) antibodies | |
| AU2018312441B2 (en) | Antibody binding active alpha-synuclein | |
| JP7065516B2 (ja) | アミロイドベータのn末端エピトープおよびそれに対する立体配座選択的抗体 | |
| CA3100896C (en) | Anti-abeta antibodies and uses thereof | |
| CN114945592A (zh) | 抗-α-突触核蛋白单克隆抗体及其使用方法 | |
| JP2026503664A (ja) | 抗aベータ抗体を用いた神経障害の治療方法 | |
| EP3574020A1 (en) | Antibodies to amyloid beta | |
| HK40040248A (en) | Anti-abeta antibodies and uses thereof | |
| HK40040248B (en) | Anti-abeta antibodies and uses thereof | |
| EA041243B1 (ru) | Антитела к бета-амилоидному пептиду n3pglu и их применение | |
| EA048027B1 (ru) | АНТИТЕЛА К α-СИНУКЛЕИНУ И ИХ ПРИМЕНЕНИЯ | |
| BR122024022779A2 (pt) | Molécula de ácido nucleico, célula de mamífero, processo para produzir um anticorpo anti-n3pg ab |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220512 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220512 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20220512 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220621 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220920 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221118 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20221213 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230111 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7210612 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |